{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:48:01Z","timestamp":1782452881528,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd008907.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000}}],"reference-count":28,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008907.pub4","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T04:36:05Z","timestamp":1624336565000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2021","author":[{"given":"Xian-Chao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology; Hwa Mei Hospital, University of Chinese Academy of Sciences; Ningbo China"},{"name":"Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences; Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine; The Second People\u2019s Hospital of Hefei City; Hefei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine; Wenzhou Medical University; Wenzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology; The First Affiliated Hospital of Wenzhou Medical University; Wenzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ke","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurology; Hwa Mei Hospital, University of Chinese Academy of Sciences; Ningbo China"},{"name":"Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences; Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Yuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Neurology; The First Affiliated Hospital of Wenzhou Medical University; Wenzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"2-3","key":"10.1002\/14651858.CD008907.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Research"},{"issue":"3","key":"10.1002\/14651858.CD008907.pub4-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD008907.pub4-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD008907.pub4-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2018.01.029","article-title":"Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures","volume":"81","author":"J\u00f3\u017awiak","year":"2018","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"106962","DOI":"10.1016\/j.yebeh.2020.106962","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial","volume":"105","author":"Kirkham","year":"2020","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Sperling MR Abou-Khalil B Harvey J Rogin JB Biraben A Galimberti CA Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial Epilepsia 2015 56 2 244 53 10.1111\/epi.12894 25528898","DOI":"10.1111\/epi.12894"},{"issue":"5","key":"10.1002\/14651858.CD008907.pub4-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ane.12734","article-title":"Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study","volume":"136","author":"Chaves","year":"2017","journal-title":"Acta Neurologica Scandinavica"},{"issue":"10","key":"10.1002\/14651858.CD008907.pub4-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s00115-016-0199-5","article-title":"Anticonvulsant add-on therapy with eslicarbazepine acetate: results of the EPOS-study in adults in Germany","volume":"87","author":"Losch","year":"2016","journal-title":"Nervenarzt"},{"issue":"1","key":"10.1002\/14651858.CD008907.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.yebeh.2017.04.019","article-title":"Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials","volume":"72","author":"Biton","year":"2017","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0012|cit12","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0013|cit13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"49306\u201349324","DOI":"10.1109\/ACCESS.2018.2867078","article-title":"Focal and non-focal epilepsy localization: A review","volume":"6","author":"Hussein A","year":"2018","journal-title":"IEEE Access"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6. Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604.ch4"},{"issue":"1","key":"10.1002\/14651858.CD008907.pub4-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/0023210-200923010-00005","article-title":"Eslicarbazepine acetate","volume":"23","author":"McCormack","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0018|cit18","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"issue":"2","key":"10.1002\/14651858.CD008907.pub4-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1517\/13543780802635107","article-title":"Eslicarbazepine acetate: a new option for the treatment of focal epilepsy","volume":"18","author":"Mestre","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0020|cit20","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"2","key":"10.1002\/14651858.CD008907.pub4-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/01.wco.0000063766.15877.8e","article-title":"The epidemiology of epilepsy revisited","volume":"16","author":"Sander","year":"2003","journal-title":"Current Opinion in Neurology"},{"issue":"4","key":"10.1002\/14651858.CD008907.pub4-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD008907.pub4-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1474-4422(08)70108-X","article-title":"Intractable epilepsy: management and therapeutic alternatives","volume":"7","author":"Schuele","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604.ch15"},{"key":"10.1002\/14651858.CD008907.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1212\/wnl.49.2.333","article-title":"Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs","volume":"49(2)","author":"Walker","year":"1997","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD008907.pub4-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008907","article-title":"Eslicarbazepine acetate add-on for drug-resistant partial epilepsy","author":"Chang","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD008907.pub4-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008907.pub2","article-title":"Eslicarbazepine acetate add-on for drug-resistant partial epilepsy","author":"Chang","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008907.pub4-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008907.pub3","article-title":"Eslicarbazepine acetate add-on for drug-resistant focal epilepsy","author":"Chang","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:20:00Z","timestamp":1782451200000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008907.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008907.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}